The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Since October 2020 – when the Health Sciences Authority (HSA) first authorized sale of an esketamine nasal spray for serious ... numbers for Singapore, but Spravato is available at about 2,800 ...
Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal ... the ketamine nasal spray Spravato is now a mainstream prescription for treatment ...
In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...
J&J is already a player in the market for drugs to treat resistant MDD with nasal spray antidepressant Spravato (esketamine), which made $780 million in the first nine months of 2024, along with ...
Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious ... Once seen as an alternative option, the ketamine nasal spray Spravato ...
Since October 2020 – when the Health Sciences Authority (HSA) first authorised sale of an esketamine nasal spray for serious ... Once seen as an alternative option, the ketamine nasal spray Spravato ...
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant ... has published its final report on Spravato (esketamine) and says the drug would need to be between 25% and ...